Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs
Diabetic kidney disease (DKD) is a major health problem and one of the leading causes of end-stage renal disease worldwide. Despite recent advances, there exists an urgent need for the development of new treatments for DKD. DKD is characterized by the excessive synthesis and deposition of extracellu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.587689/full |
| _version_ | 1818864175163637760 |
|---|---|
| author | Hiroko Sakuma Shinji Hagiwara Shinji Hagiwara Phillip Kantharidis Tomohito Gohda Yusuke Suzuki |
| author_facet | Hiroko Sakuma Shinji Hagiwara Shinji Hagiwara Phillip Kantharidis Tomohito Gohda Yusuke Suzuki |
| author_sort | Hiroko Sakuma |
| collection | DOAJ |
| description | Diabetic kidney disease (DKD) is a major health problem and one of the leading causes of end-stage renal disease worldwide. Despite recent advances, there exists an urgent need for the development of new treatments for DKD. DKD is characterized by the excessive synthesis and deposition of extracellular matrix proteins in glomeruli and the tubulointerstitium, ultimately leading to glomerulosclerosis as well as interstitial fibrosis. Renal fibrosis is the final common pathway at the histological level leading to an end-stage renal failure. In fact, activation of the nuclear factor erythroid 2-related factor 2 pathway by bardoxolone methyl and inhibition of transforming growth factor beta signaling by pirfenidone have been assumed to be effective therapeutic targets for DKD, and various basic and clinical studies are currently ongoing. MicroRNAs (miRNAs) are endogenously produced small RNA molecules of 18–22 nucleotides in length, which act as posttranscriptional repressors of gene expression. Studies have demonstrated that several miRNAs contribute to renal fibrosis. In this review, we outline the potential of using miRNAs as an antifibrosis treatment strategy and discuss their clinical application in DKD. |
| first_indexed | 2024-12-19T10:27:28Z |
| format | Article |
| id | doaj.art-be708c7ecaa9431a8f4a67d4265ac6be |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-19T10:27:28Z |
| publishDate | 2020-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-be708c7ecaa9431a8f4a67d4265ac6be2022-12-21T20:25:51ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-11-011110.3389/fphar.2020.587689587689Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAsHiroko Sakuma0Shinji Hagiwara1Shinji Hagiwara2Phillip Kantharidis3Tomohito Gohda4Yusuke Suzuki5Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, JapanDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo, JapanDepartment of Kidney and Hypertension, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, JapanDepartment of Diabetes, Monash University, Melbourne, VIC, AustraliaDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo, JapanDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo, JapanDiabetic kidney disease (DKD) is a major health problem and one of the leading causes of end-stage renal disease worldwide. Despite recent advances, there exists an urgent need for the development of new treatments for DKD. DKD is characterized by the excessive synthesis and deposition of extracellular matrix proteins in glomeruli and the tubulointerstitium, ultimately leading to glomerulosclerosis as well as interstitial fibrosis. Renal fibrosis is the final common pathway at the histological level leading to an end-stage renal failure. In fact, activation of the nuclear factor erythroid 2-related factor 2 pathway by bardoxolone methyl and inhibition of transforming growth factor beta signaling by pirfenidone have been assumed to be effective therapeutic targets for DKD, and various basic and clinical studies are currently ongoing. MicroRNAs (miRNAs) are endogenously produced small RNA molecules of 18–22 nucleotides in length, which act as posttranscriptional repressors of gene expression. Studies have demonstrated that several miRNAs contribute to renal fibrosis. In this review, we outline the potential of using miRNAs as an antifibrosis treatment strategy and discuss their clinical application in DKD.https://www.frontiersin.org/articles/10.3389/fphar.2020.587689/fulldiabetic kidney diseasemicroRNArenal fibrosisend-stage renal diseaseantifibrosis treatment |
| spellingShingle | Hiroko Sakuma Shinji Hagiwara Shinji Hagiwara Phillip Kantharidis Tomohito Gohda Yusuke Suzuki Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs Frontiers in Pharmacology diabetic kidney disease microRNA renal fibrosis end-stage renal disease antifibrosis treatment |
| title | Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs |
| title_full | Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs |
| title_fullStr | Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs |
| title_full_unstemmed | Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs |
| title_short | Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs |
| title_sort | potential targeting of renal fibrosis in diabetic kidney disease using micrornas |
| topic | diabetic kidney disease microRNA renal fibrosis end-stage renal disease antifibrosis treatment |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2020.587689/full |
| work_keys_str_mv | AT hirokosakuma potentialtargetingofrenalfibrosisindiabetickidneydiseaseusingmicrornas AT shinjihagiwara potentialtargetingofrenalfibrosisindiabetickidneydiseaseusingmicrornas AT shinjihagiwara potentialtargetingofrenalfibrosisindiabetickidneydiseaseusingmicrornas AT phillipkantharidis potentialtargetingofrenalfibrosisindiabetickidneydiseaseusingmicrornas AT tomohitogohda potentialtargetingofrenalfibrosisindiabetickidneydiseaseusingmicrornas AT yusukesuzuki potentialtargetingofrenalfibrosisindiabetickidneydiseaseusingmicrornas |